An advisory committee to the powerful US Food and Drug Administration (FDA) has voted nine to one in favour of a Mesoblast drug to treat transplant rejections in children.
The verdict was delivered by the Oncologic Drugs Advisory Committee (ODAC) about 7am AEST on Friday.
Loading...
Tom Richardson was a journalist at The Australian Financial Review
Carrie LaFrenz is a senior journalist covering retail/consumer goods. She previously covered healthcare/biotech. Carrie has won multiple awards for her journalism including financial journalist of the year from The National Press Club. Connect with Carrie on Twitter. Email Carrie at carrie.lafrenz@afr.com
